Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) — Naperville, Illinois

Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) is a clinical research site located in Naperville, Illinois, United States 60540.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075)?

Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) conducted?

Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) has 1 clinical trials on record, with 1 currently active. Their work covers Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms.

Is Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) accredited by Crixeo Health?

Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.